RT Journal Article
SR Electronic
T1 Local emergence and decline of a SARS-CoV-2 variant with mutations L452R and N501Y in the spike protein
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.27.21254849
DO 10.1101/2021.04.27.21254849
A1 Mallm, Jan-Philipp
A1 Bundschuh, Christian
A1 Kim, Heeyoung
A1 Weidner, Niklas
A1 Steiger, Simon
A1 Lander, Isabelle
A1 Börner, Kathleen
A1 Bauer, Katharina
A1 Hübschmann, Daniel
A1 Benes, Vladimir
A1 Rausch, Tobias
A1 de Azevedo, Nayara Trevisan Doimo
A1 Telzerow, Anja
A1 Jost, Katharina Laurence
A1 Parthé, Sylvia
A1 Schnitzler, Paul
A1 Boutros, Michael
A1 Müller, Barbara
A1 Bartenschlager, Ralf
A1 Kräusslich, Hans-Georg
A1 Rippe, Karsten
YR 2021
UL http://medrxiv.org/content/early/2021/04/29/2021.04.27.21254849.abstract
AB Variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are replacing the initial wild-type strain, jeopardizing current efforts to contain the pandemic. Amino acid exchanges in the spike protein are of particular concern as they can render the virus more transmissible or reduce vaccine efficacy. Here, we conducted whole genome sequencing of SARS-CoV-2 positive samples from the Rhine-Neckar district in Germany during January-March 2021. We detected a total of 166 samples positive for a variant with a distinct mutational pattern in the spike gene comprising L18F, L452R, N501Y, A653V, H655Y, D796Y and G1219V with a later gain of A222V. This variant was designated A.27.RN according to its phylogenetic clade classification. It emerged in parallel with the B.1.1.7 variant, increased to >50% of all SARS-CoV-2 variants by week five. Subsequently it decreased to <10% of all variants by calendar week eight when B.1.1.7 had become the dominant strain. Antibodies induced by BNT162b2 vaccination neutralized A.27.RN but with a two-to-threefold reduced efficacy as compared to the wild-type and B.1.1.7 strains. These observations strongly argue for continuous and comprehensive monitoring of SARS-CoV-2 evolution on a population level.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the program for surveillance and control of SARS-CoV-2 mutations of the state of Baden-Württemberg, the German Federal Research Network Applied Surveillance and Testing (B-FAST) within the Network University Medicine and the DKFZ@fightCOVID initiative.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the ethics committee of the Medical Faculty at the University of Heidelberg for the analysis of proband samples by whole genome sequencing of the viral RNA (S 316/2021) as well as the virus propagation and neutralization assays and use of sera from vaccinated donors (S-203/2021).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSARS-CoV-2 viral genome sequences have been uploaded to the DESH database (https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/DESH/DESH.html) of the Robert Koch Institute, which will make the data available via the GISAID (https://www.gisaid.org) database and the European Nucleotide Archive (ENA, https://www.ebi.ac.uk/ena/browser/home). Representative sequences of A.27.RN with and without the A222V mutation are included as Supplementary Data.